Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

647 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).
Lambert-Niclot S, Grude M, Chaix ML, Charpentier C, Reigadas S, Le Guillou-Guillemette H, Rodallec A, Amiel C, Maillard A, Dufayard J, Mourez T, Mirand A, Guinard J, Montes B, Vallet S, Marcelin AG, Descamps D, Flandre P, Delaugerre C, Morand-Joubert L; ANRS AC-11 Resistance Group. Lambert-Niclot S, et al. Among authors: descamps d. J Antimicrob Chemother. 2018 Aug 1;73(8):2147-2151. doi: 10.1093/jac/dky142. J Antimicrob Chemother. 2018. PMID: 29718247
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).
Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vézinet F. Descamps D, et al. JAMA. 2000 Jan 12;283(2):205-11. doi: 10.1001/jama.283.2.205. JAMA. 2000. PMID: 10634336 Clinical Trial.
Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors.
Masquelier B, Race E, Tamalet C, Descamps D, Izopet J, Buffet-Janvresse C, Ruffault A, Mohammed AS, Cottalorda J, Schmuck A, Calvez V, Dam E, Fleury H, Brun-Vézinet F; ANRS AC11 Resistance study group. French Agence Nationale de Recherches sur le SIDA. Masquelier B, et al. Among authors: descamps d. Antimicrob Agents Chemother. 2001 Jun;45(6):1836-42. doi: 10.1128/AAC.45.6.1836-1842.2001. Antimicrob Agents Chemother. 2001. PMID: 11353634 Free PMC article.
Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study.
Descamps D, Calvez V, Izopet J, Buffet-Janvresse C, Schmuck A, Colson P, Ruffault A, Maillard A, Masquelier B, Cottalorda J, Harzic M, Brun-Vézinet F, Costagliola D; ANRS Antiretroviral Resistance Study Group. Descamps D, et al. AIDS. 2001 Sep 28;15(14):1777-82. doi: 10.1097/00002030-200109280-00005. AIDS. 2001. PMID: 11579238
Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy.
Mouroux M, Descamps D, Izopet J, Yvon A, Delaugerre C, Matheron S, Coutellier A, Valantin MA, Bonmarchand M, Agut H, Massip P, Costagliola D, Katlama C, Brun-Vezinet F, Calvez V. Mouroux M, et al. Among authors: descamps d. Antivir Ther. 2001 Sep;6(3):179-83. Antivir Ther. 2001. PMID: 11808752
Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.
Damond F, Brun-Vezinet F, Matheron S, Peytavin G, Campa P, Pueyo S, Mammano F, Lastere S, Farfara I, Simon F, Chene G, Descamps D. Damond F, et al. Among authors: descamps d. J Clin Microbiol. 2005 Jan;43(1):484-7. doi: 10.1128/JCM.43.1.484-487.2005. J Clin Microbiol. 2005. PMID: 15635022 Free PMC article. Clinical Trial.
Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study.
Landman R, Descamps D, Peytavin G, Trylesinski A, Katlama C, Girard PM, Bonnet B, Yeni P, Bentata M, Michelet C, Benalycherif A, Brun Vezinet F, Miller MD, Flandre P; TONUS (IMEA 021) Study Group. Landman R, et al. Among authors: descamps d. HIV Clin Trials. 2005 Nov-Dec;6(6):291-301. doi: 10.1310/9DQP-R7JA-75ED-RBCP. HIV Clin Trials. 2005. PMID: 16452063 Clinical Trial.
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
Masquelier B, Assoumou KL, Descamps D, Bocket L, Cottalorda J, Ruffault A, Marcelin AG, Morand-Joubert L, Tamalet C, Charpentier C, Peytavin G, Antoun Z, Brun-Vézinet F, Costagliola D; ANRS Resistance Study Group. Masquelier B, et al. Among authors: descamps d. J Antimicrob Chemother. 2008 Jun;61(6):1362-8. doi: 10.1093/jac/dkn127. Epub 2008 Apr 4. J Antimicrob Chemother. 2008. PMID: 18390885
647 results